Purpose: Retinoblastoma is rare disease but potentially fatal if left untreated. This study aimed to evaluate demographic profile, treatment and complications in survivors of retinoblastoma in tertiary care center in 2019. Method: This is multicentric hospital based cross sectional study conducted from January 2019 to December 2019 after ethical clearance from National Health Research Council. All post-treatment cases of retinoblastoma who had completed at least 1-year follow-up examination in any of our retinoblastoma (RB) center in 2019 were included whereas newly diagnosed and ongoing treatment cases and those failed to consent were excluded. Data based on demographic profile, ethnic and geographical distribution of RB survivors was collected and entered into Microsoft Excel 2016. Statistical analysis was performed using Statistical Package for Social Sciences version 20. Result: A total of 37 RB survivors that included 24(64.9%) female and 13(35.1%) male. Of the total, 34 (91.8%) survivors had unilateral (Right Eye 18, Left Eye 16) involvement whereas 3(8.1%) bilateral involvement. The mean age at diagnosis and study time was 38.65 ± 37.43 months (3-214 months) and 93.46 ± 65.58 months (16-252 months) respectively. Primary enucleation was commonest mode of treatment (64.9%). Majority of survivors belonged to upper caste group 20(54.1%) and mostly from Bagmati 15(40.5%) followed by province-2 (21.6%). Conclusion: Descriptive study showed that most of survivors had undergone enucleation due to delayed presentation with poor prognosis. Early diagnosis and appropriate treatment modality are prerequisite for salvaging life of child, sight and eyeball.